Analyst Jailendra Singh of Truist Financial maintained a Hold rating on GoodRx Holdings (GDRX – Research Report), with a price target of $6.50.
Jailendra Singh has given his Hold rating due to a combination of factors influencing GoodRx Holdings. The company is undergoing a leadership change with a new CEO and CFO, which is not expected to result in significant shifts in operational focus or financial targets in the near term. Expectations are that GoodRx will meet its Q4 consensus and guide 2025 in line with previous commentary, indicating modest growth.
Despite some positive macro trends, the uncertain pharmacy environment and evolving issues with pharmacy reimbursement and administration fees pose challenges. The company’s revenue growth is projected to be in the low single digits, with prescription revenues remaining flat and some growth anticipated in pharma manufacturer solutions. These factors, combined with the historical volatility in share price post-earnings reports, contribute to the Hold rating.